CONCORD BIOTECH LIMITED Valuation
CONCORDBIO · Healthcare · Current price ₹1,455.3
Is CONCORD BIOTECH LIMITED undervalued?
DocStoX estimates the fair value of CONCORD BIOTECH LIMITED at ₹640 per share, versus the current market price of ₹1,455. That puts the stock about -56.1% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹216), Relative P/E (₹984), Graham floor (₹331), Analyst target (₹1,506). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹216 (bear) to ₹640 (base) to ₹1,506 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
CONCORD BIOTECH LIMITED trades at a P/E of 57.8x and a P/B of 7.7x, with a dividend yield of 0.5%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on CONCORD BIOTECH LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.